ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018
T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma.
Abstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 453 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
453citing papers in PubMed, 3 pooled it
20.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
453 citing papers in PubMed, 3 syntheses or guidelines pooled it, 623 citations in OpenAlex.
- T cell immunity in glioma and potential implications for immunotherapy: A systematic review.Neuro-oncology · 2026Pooled it
- Anti-PD-1 and anti-PD-L1 antibodies for glioma.The Cochrane database of systematic reviews · 2025Pooled it
- Pooled it
- A phase 2, open label, clinical trial of pre-surgical and adjuvant treatment of recurrent glioblastoma with tremelimumab and durvalumab alone and in combination.Journal of neuro-oncology · 2026Trial
- Article
- The 15-year bibliometric landscape of glioblastoma vaccines: Emergence of combinatorial immunotherapy.Human vaccines & immunotherapeutics · 2026Review
- Abundant CD8British journal of cancer · 2026Article
- The Microbiome in Glioblastoma: Mechanisms, Tumor-Immune Interactions, and Translational Perspectives.MicrobiologyOpen · 2026Review
- STRA6-mediated ferroptosis and its potential association with antioxidant stress pathways in glioblastoma.iScience · 2026Article
- Generation of Allogeneic CAR-T Circumvents Functional Deficits in Patient-Derived Autologous Product for Glioblastoma.International journal of cancer · 2026Article
- Article
- Immunotherapy for Glioma: A compartmental framework for resistance and rational combination design.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Review
- Construction Strategies, Microenvironmental Modelling and Precision-Therapy Applications of Glioma Organoid Models.Cancers · 2026Review
- EFEMP2 Is Associated with Shelterin-Related DNA Damage Repair, Immune Microenvironment Features, and Prognosis in Glioblastoma.Biomedicines · 2026Article
- Review
- Mechanisms of Therapeutic Resistance and Recent Advances in Glioblastoma Treatment.Immunology and cell biology · 2026Review
- Perioperative myeloid cell remodeling shapes CAR-T cell efficacy in glioblastoma.Nature communications · 2026Article
- Tumor infiltrating lymphocytes in glioblastoma: immunobiology and translational implications.NPJ precision oncology · 2026Review
- The Hallmarks of Glioblastoma: Functional Interplay Between Long Non-Coding RNAs and RNA-Binding Proteins.Cells · 2026Review
- Tumor and Stromal Sphingolipid Imbalance Are Associated with T Cell Tissue Residency in Glioblastoma.Cancers · 2026Article
393 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 6 institutions in 1 country.
Karolina WoronieckaDuke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina.
Pakawat ChongsathidkietDuke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina.ORCID 0000-0001-5363-3061
Kristen RhodinDuke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina.
Hanna KemenyDuke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina.
Cosette DechantDuke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina.
S Harrison FarberDuke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina.
Aladine A ElsamadicyDuke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina.
Xiuyu CuiDuke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina.
Shohei KoyamaDepartment of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute, Boston, Massachusetts.
Christina JacksonDepartment of Neurosurgery, Johns Hopkins University, Baltimore, Maryland.
Landon J HansenDepartment of Pharmacology and Molecular Cancer Biology, Duke University, Durham, North Carolina.
Tanner M JohannsDivision of Medical Oncology, Department of Medicine, Washington University, St. Louis, Missouri.
Luis Sanchez-PerezDuke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina.
Vidyalakshmi ChandramohanDepartment of Neurosurgery, Duke University Medical Center, Durham, North Carolina.
Yen-Rei Andrea YuDepartment of Medicine, Duke University Medical Center, Durham, North Carolina.
Darell D BignerDepartment of Neurosurgery, Duke University Medical Center, Durham, North Carolina.
Amber GilesNeuro-oncology Division, National Institutes of Health, Bethesda, Maryland.
Patrick HealyDepartment of Biostatistics, Duke University, Durham, North Carolina.
Glenn DranoffDepartment of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute, Boston, Massachusetts.
Kent J WeinholdDepartment of Surgery, Duke University Medical Center, Durham, North Carolina.
Gavin P DunnDepartment of Neurological Surgery, Center for Human Immunology and Immunotherapy Programs, Washington University, St. Louis, Missouri.
Peter E FecciDuke Brain Tumor Immunotherapy Program, Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina. peter.fecci@duke.edu.
Duke University · USDana-Farber Cancer Institute · USHope Center for Neurological Disorders · USJohns Hopkins University · USNational Institutes of Health · USWashington University in St. Louis · US
Funding
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007171 · NIGMS · DUKE UNIVERSITY · PI KONTOS, CHRISTOPHER D · 1985 to 2021
$31.2MTargeted Alpha-Particle Radiotheraphy of Brain Tumors with 211At-81C6 AntibodyP50CA190991 · NCI · DUKE UNIVERSITY · PI HERNDON, JAMES E · 2014 to 2023
$20.8MClinical Brain Tumor Development of a Cytomegalovirus-targeted Therapeutic with Vaccine pre-conditioning to Validate Novel Predictors of Vaccine EfficacyR01CA235612 · NCI · DUKE UNIVERSITY · PI SAMPSON, JOHN H. · 2019 to 2022
$2.0MIMMUNOBIOLOGY OF MALIGNANT GLIOMAK08NS092912 · NINDS · WASHINGTON UNIVERSITY · PI DUNN, GAVIN PETER · 2015 to 2019
$877kNCI NIH HHS P50 CA190991NCI NIH HHS R01 CA235612NIGMS NIH HHS T32 GM007171NINDS NIH HHS K08 NS092912
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAgedAged, 80 and overAnimalsCD8-Positive T-LymphocytesFemaleFlow CytometryGene Expression Regulation, NeoplasticGlioblastomaHumansInterferon-gammaInterleukin-2Lymphocytes, Tumor-InfiltratingMaleMiceMiddle AgedIFNG protein, humanIL2 protein, humanInterferon-gammaInterleukin-2Receptors, Antigen, T-Cell, alpha-betaTumor Necrosis Factor-alpha
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.